ES2097783T3 - Nanomatrices proteicas y procedimiento de produccion. - Google Patents
Nanomatrices proteicas y procedimiento de produccion.Info
- Publication number
- ES2097783T3 ES2097783T3 ES91120485T ES91120485T ES2097783T3 ES 2097783 T3 ES2097783 T3 ES 2097783T3 ES 91120485 T ES91120485 T ES 91120485T ES 91120485 T ES91120485 T ES 91120485T ES 2097783 T3 ES2097783 T3 ES 2097783T3
- Authority
- ES
- Spain
- Prior art keywords
- nanomatrices
- protein
- ingredient
- reversible
- protein ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/922—Colloid systems having specified particle size, range, or distribution, e.g. bimodal particle distribution
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
ESTA INVENCION SE REFIERE A UN METODO DE PRODUCIR NONOMATRICES ESTABILIZADAS Y REVERSIBLES. EL PROCEDIMIENTO ESENCIAL DE ESTA INVENCION INCLUYE: LA DISOLUCION DE UN PRIMER INGREDIENTE PROTEINICO EN UN BUFER CON UNA OSMOLARIDAD ADECUADA, AÑADIENDO UN SEGUNDO INGREDIENTE PROTEINICO QUE ES DIFERENTE DEL PRIMERO; Y AÑADIR UNA SOLUCION QUE CONTENGA UN SOLVENTE ORGANICO NEUTRO. LA MEZCLA DE LAS SUSTANCIAS ANTERIORES DA COMO RESULTADO UNA SUSPENSION TURBIA QUE CONTIENE NANOMATRICES. UN SURFACTANTE OPCIONAL PUEDE SER AÑADIDO ADEMAS DEL SEGUNDO INGREDIENTE PROTEINICO. UN AGENTE DEGRADANTE OPCIONAL PUEDE SER TAMBIEN AÑADIDO ANTES O DESPUES DE LA FORMACION DE LAS NANOMATRICES. EL PRODUCTO RESULTANTE DE ESTA INVENCIO ES UN PRODUCTO ESTABILIZADO Y REVERSIBLE QUE COMPRENDE NANOMATRICES PROTEINICAS PARA LLEVAR AL MENOS UN INGREDIENTE BIOLOGICAMENTE INTERACTIVO QUE PUEDE ESTAR UNIDO COVALENTEMENTE A LA PROTEINA O ATRAPADO DENTRO DE LA NANOMATRIZ O ABSORBIDA EN LA SUPERFICIES DE LOS INGRENDIENTES PROTEINICOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64172091A | 1991-01-15 | 1991-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2097783T3 true ES2097783T3 (es) | 1997-04-16 |
Family
ID=24573583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91120485T Expired - Lifetime ES2097783T3 (es) | 1991-01-15 | 1991-11-29 | Nanomatrices proteicas y procedimiento de produccion. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5308620A (es) |
EP (1) | EP0495187B1 (es) |
AT (1) | ATE147976T1 (es) |
DE (1) | DE69124357T2 (es) |
DK (1) | DK0495187T3 (es) |
ES (1) | ES2097783T3 (es) |
GR (1) | GR3022703T3 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5725804A (en) * | 1991-01-15 | 1998-03-10 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US6391343B1 (en) | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US5783214A (en) * | 1994-06-13 | 1998-07-21 | Buford Biomedical, Inc. | Bio-erodible matrix for the controlled release of medicinals |
US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US5716643A (en) * | 1995-06-07 | 1998-02-10 | Hemosphere Inc. | Large scale production of medicine coated crosslinked protein microspheres |
EP1683517A1 (en) | 1996-08-19 | 2006-07-26 | American Bioscience, Inc. | Methods for the production of protein particles useful for delivery of pharmacological agents |
US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
ES2232862T3 (es) * | 1996-10-21 | 2005-06-01 | Quadrant Drug Delivery Limited | Sustitutos de plaquetas y procedimientos de conjugacion apropiados para su preparacion. |
AU7133898A (en) * | 1997-04-18 | 1998-11-13 | Vertex Pharmaceuticals Incorporated | Nanosized aspartyl protease inhibitors |
AU741528B2 (en) | 1997-06-05 | 2001-12-06 | Hemosphere, Inc. | Fibrinogen-coated microspheres |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
HU230338B1 (hu) * | 1997-06-27 | 2016-02-29 | Abraxis Bioscience Llc | Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására |
WO1999016420A1 (en) * | 1997-09-29 | 1999-04-08 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in nebulizers |
ES2205560T5 (es) * | 1997-09-29 | 2013-04-16 | Novartis Ag | Preparaciones estabilizadas para usar en inhaladores de dosis medida |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
IN187039B (es) * | 1997-12-08 | 2001-12-29 | Council Scient Ind Res | |
WO2000000215A1 (en) * | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
CA2382133C (en) | 2000-05-10 | 2010-11-23 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US6605311B2 (en) * | 2000-06-22 | 2003-08-12 | The Procter & Gamble Company | Insoluble protein particles |
US7141236B2 (en) * | 2000-07-28 | 2006-11-28 | Nektar Therapeutics | Methods and compositions for delivering macromolecules to or via the respiratory tract |
JP2005514393A (ja) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | アミノグリコシドの肺への供給 |
US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US7229966B2 (en) * | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
JP2006516262A (ja) * | 2002-12-17 | 2006-06-29 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | Y2受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法 |
US7186692B2 (en) * | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
JP5390070B2 (ja) * | 2003-02-07 | 2014-01-15 | プロメティック、バイオサイエンシーズ、インコーポレーテッド | 赤血球形成刺激薬としての中鎖脂肪酸、グリセリド、および類似体 |
DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE372421B (es) * | 1968-04-01 | 1974-12-23 | Minnesota Mining & Mfg | |
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
DK143689C (da) | 1975-03-20 | 1982-03-15 | J Kreuter | Fremgangsmaade til fremstilling af en adsorberet vaccine |
HU189251B (en) * | 1982-04-07 | 1986-06-30 | Asahi Kasei Kogyo Kk,Jp | Process for stabilizing tumor necrosis factor |
US4671954A (en) * | 1983-12-13 | 1987-06-09 | University Of Florida | Microspheres for incorporation of therapeutic substances and methods of preparation thereof |
FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
-
1991
- 1991-11-29 AT AT91120485T patent/ATE147976T1/de not_active IP Right Cessation
- 1991-11-29 DE DE69124357T patent/DE69124357T2/de not_active Expired - Fee Related
- 1991-11-29 EP EP91120485A patent/EP0495187B1/en not_active Expired - Lifetime
- 1991-11-29 ES ES91120485T patent/ES2097783T3/es not_active Expired - Lifetime
- 1991-11-29 DK DK91120485.7T patent/DK0495187T3/da active
-
1992
- 1992-10-13 US US07/959,560 patent/US5308620A/en not_active Expired - Lifetime
-
1997
- 1997-02-27 GR GR970400390T patent/GR3022703T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0495187B1 (en) | 1997-01-22 |
DE69124357D1 (de) | 1997-03-06 |
ATE147976T1 (de) | 1997-02-15 |
DE69124357T2 (de) | 1997-07-10 |
GR3022703T3 (en) | 1997-05-31 |
EP0495187A1 (en) | 1992-07-22 |
US5308620A (en) | 1994-05-03 |
DK0495187T3 (da) | 1997-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2097783T3 (es) | Nanomatrices proteicas y procedimiento de produccion. | |
ES2118677T3 (es) | Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion. | |
ES2117052T3 (es) | Induccion de respuestas de linfocitos t citotoxicos. | |
AR002255A1 (es) | Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion. | |
ES2131573T3 (es) | Procedimiento para el replegamiento de igf-i a una conformacion activa. | |
ES2134360T3 (es) | Formulaciones de perfume. | |
MX9303569A (es) | Composiciones de concentrado de agente tensioactivo ajustado en viscosidad. | |
NO992068L (no) | Mikroemulsjon og fremgangsmÕte for fremstilling av denne | |
ATE72229T1 (de) | Verfahren zur herstellung von serin-n,ndiessigs|ure und derivaten. | |
ES2059761T3 (es) | Mejoras en fungicidas o relativas a los mismos. | |
DE69033874D1 (de) | Verfahren zur Herstellung von arzneimittelenthaltenden gefriergetrockneten Formulierungen | |
MX9401211A (es) | Composicion y procedimiento para combatir la aglomeracion de abonos. | |
ES2187820T3 (es) | Formulaciones farmaceuticas de factor de liberacion de la corticotrop ina que tiene una estabilidad en su forma liquida. | |
FI935051A (fi) | Lanolinderivat som penetrationfraemjande aemnen och anvaendning av dessa i preparat innehaollande laekemedel eller andra biologiskt aktiva substanser | |
ES2131673T3 (es) | Solucion que contiene igf-1. | |
UY27229A1 (es) | Composición | |
ES2053039T3 (es) | Procedimiento para impedir el cambio de color de los alimentos. | |
ES2068240T3 (es) | Composicion detergente. | |
ES2042468T3 (es) | Producto para la fijacion del cabello. | |
ATE168115T1 (de) | In lösung bringen von proteinen in aktiver form | |
ES2183333T3 (es) | Metodo para producir peliculas celulosicas tubulares. | |
ES2162111T3 (es) | Metodo para lavar botellas. | |
MX9302924A (es) | Agente para tratamiento de cataratas y metodo para su preparacion. | |
PE20001244A1 (es) | Formulaciones antiparasitos que contienen doramectina | |
ES2033000T3 (es) | Caucho que contiene antidegradantes en una matriz. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 495187 Country of ref document: ES |